(secondQuint)A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults.

 This was a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of MEDI8897 compared to placebo when administered to healthy adult participants.

 There were 136 participants randomized to receive MEDI8897 or placebo at one site.

 Investigational product was delivered intravenously (IV) to 3 cohorts and intramuscularly (IM) to 2 cohorts.

 4 different dose levels of investigational product were evaluated across the 5 cohorts.

 Participants were followed for approximately 1 year.

.

 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults@highlight

The purpose of this study was to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy adult participants.

